|
This week we get back to our interview with Dr. Aaron Vinik, Director, EVMS Strelitz Diabetes Research Center. He has been at the forefront in developing new technologies for growing and regenerating beta cells. Our publisher, Steve Freed, had a few questions for him on how he views the use of GLP-1 agonists and if they may have a future role in the regeneration of beta cells.
We also have a special interview with Dr. Steven Edelman, founder and Director of TCOYD, and his use of GLP-1 drugs for his patients.
Our survey of medical professionals had some interesting data on issues such as storage and priming, and you may be surprised to find out what your colleagues had to say. in this week's Clinical Case Study, we look at Mark, a 55-year-old white man, who was diagnosed with type 2 diabetes 3 years ago and is not at target. |
